Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study

Jerry Tan; James Del Rosso; Jonathan Weiss; Linda Stein Gold; Fran Cook-Bolden; Lawrence Eichenfeld; Emil Tanghetti; Alessandra Ali? Saenz; Faiz Ahmad

doi:10.25251/skin.4.supp.56

Jerry Tan
James Del Rosso
Jonathan Weiss
Linda Stein Gold
Fran Cook-Bolden
Lawrence Eichenfeld
Emil Tanghetti
Alessandra Ali? Saenz
Faiz Ahmad

Keywords

Acne Vulgaris, Acne, trifarotene, retinoid, Safety

Abstract

Abstract not available.

References

1. Tan J, Thiboutot D, Popp G, Gooderham M, Lynde C, Del Rosso J, et al. Randomized phase 3 evaluation of trifarotene 50 mg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80:1691-9.

2. Blume-Peytavi U, Fowler J, Lajos K, Draelos Z, Cook-Bolden F, Dirschka T, et al. Long-term safety and efficacy of trifarotene 50μg/g cream, a first-inclass RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2019:(In preparation).

Poster PDF

Published

Sep 2, 2020

DOI https://doi.org/10.25251/skin.4.supp.56

How to Cite

[1]

Tan, J., Del Rosso, J., Weiss, J., Gold, L.S., Cook-Bolden, F., Eichenfeld, L., Tanghetti, E., Saenz, A.A. and Ahmad, F. 2020. Trifarotene 50 µg/G Cream for Treatment of Acne Vulgaris – A Summary of Two Randomized Trials and a Long-Term Safety Study. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s57. DOI:https://doi.org/10.25251/skin.4.supp.56.

Issue

Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)

Section

Acne & Rosacea

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

James Del Rosso, Jeffrey Sugarman , Michael Gold, Krysten Arekapdui, Lawrence Green, A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Hilary Baldwin, James Del Rosso, Leon Kircik, Linda Stein Gold, Adelaide Hebert, Evan A. Rieder, Andrew F. Alexis, Julie C. Harper, Richard G. Fried, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Emmy Graber, Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Linda Stein Gold, MD, Leon H. Kircik, MD, William Philip Werschler, MD, Hilary Baldwin, MD, Valerie Callender, MD, Lawrence Green, MD, Neil Sadick, MD, Jeffrey L. Sugarman, MD, PhD, Zoe D Draelos, MD, Emil A Tanghetti, MD, Neal Bhatia, MD, Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti, Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Lawrence Eichenfeld, Eric Simpson, Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Seth Forman, Michael Kuligowski, May Venturanza, Haobo Ren, Amy Paller, Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Lawrence Eichenfeld, Jonathan Silverberg, Robert Bissonnette, Anna Tallman, David Rubenstein, Stephen Piscitelli, John Jett, Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Lawrence Eichenfeld, Seth Forman, Michael Kuligowski, May Venturanza, Kang Sun, Eric Simpson, Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
James Del Rosso, Neal Bhatia, Hilary Baldwin, Linda Stein Gold, Seemal Desai, Sam Brantman, Critical Evaluation of Benzoyl Peroxide in Rosacea: Old Challenges and New Clinical Opportunities With Encapsulated Benzoyl Peroxide , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal Desai, Brad Glick, Howard Sofen, Anna Tallman, David Rubenstein, Janine Fournier, Philip Brown, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

<< < 1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)